Home
President's Message
Scientific & Medical Research Departments
M. D. Anderson Research News
Reports Organized by:
Researcher Name
Department
Research Center & Program
Care Center
Related Documents:
Clinical Trials
Awards
Standard Abbreviations
Disclaimer of Liability
Copyright, Contact Information, & Credits
For M. D. Anderson Staff Only:
Preparing a Research Report
Create New Research Report
Create New Division/Department Overview
Create New Faculty List
|  |
| Christopher J. Logothetis, MD
Research Interests:
Neuroendocrinology, prostatic neoplasms, genetic markers |
The primary focus of my research has been prostatic carcinomas and their treatment. With Dr. Naseema Hoosein, I have validated clinical biologic markers for prostate cancer. In collaboration with Dr. Sue-Hwa Lin (Department of Molecular Pathology), I have developed specific gene-therapy approaches for prostatic carcinoma. A trial of preoperative p53 gene therapy is under way. We have elucidated the specific function of the c-cell-adhesion molecule and have studied it in vivo. On the basis of these data, we hope to proceed soon with clinical application in collaboration with Drs. Curtis Pettaway and Louis Pisters (Department of Urology). In addition to targeting bone metastasis with Dr. Shi-Ming Tu (this department), I have proposed organ-specific therapy with bone-homing radiopharmaceuticals. We hope this approach will allow us to develop effective treatments for prostatic carcinoma.
I am continuing to direct the development of new combination cytotoxic therapies in advanced prostate cancer. This effort includes an important phase III trial in which our 4-drug regimen plus androgen ablation will be compared with androgen ablation alone as the initial treatment for nonlocalized prostate cancer. Another major focus will be the development of a strategy for the integration of this therapy in a successful approach to the treatment of prostate cancer.
In collaboration with Dr. Danai Daliani (this department), we have established a new clinical model for testing novel strategies in high-risk patients prior to prostatectomy.
Selected Publications
Amato RJ, Millikan R, Daliani D, Wood L, Logothetis C, Pollack A. Cyclophosphamide and carboplatin and selective consolidation in advanced seminoma. Clin Cancer Res 6(1):72-7, 2000
Logothetis CJ, Wu KW, Finn LD, Daliani D, Figg W, Ghaddar H, Gutterman JU. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res 7(1):1998–1203, 2001
Pagliaro L, Daliani D, Amato R, Ru SM, Jones D, Smith T, Logothetis C, Millikan R. A phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma. Cancer 89(3):615-618, 2000
Schumacher G, Bruckheimer EM, Beham AW, Honda T, Brisbay S, Roth JA, Logothetis CJ, McDonnell TJ. Molecular determinants of cell death induction following adenoviral-mediated gene transfer of wild-type p53 in prostate cancer cells. Int J Cancer 91(2):159-166, 2001
Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, Daliani D, Papandreou CN, Smith TL, Kim J, Podoloff DA, Logothetis CJ. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: A randomised phase II trial. Lancet 357:336-341, 2001
Additional Information:
|